Which company is Dacomitinib?

Dacomitinib (Dacomitinib) was approved for medical use in the United States in September 2018, in Japan in 2019, and in the European Union in 2019 for the treatment of epidermal growth factor Non-small cell lung cancer with mutated EGFR gene, is a selective and irreversible inhibitor of EGFR, developed by Pfizer Laboratories Div Pfizer Inc (Pfizer Pharmaceutical Co., Ltd.) research and development and production. Dacomitinib is designed as (2E)-N-16-4-(piperidine-1-yl)butan-2-enamide, an oral highly selective quinazoline moiety of a second-generation tyrosine kinase inhibitor, which is characterized by irreversible binding to the ATP domain of the epidermal growth factor receptor family kinase domain.